1 rich Libsyn https://www.libsyn.com 90 600 Is&amp;nbsp;tirzepatide associated with a broader reduction in cardiorenal adverse outcomes compared with dulaglutide in patients with type 2 diabetes and cardiovascular disease&amp;nbsp;(CVD?&amp;nbsp;The&amp;nbsp;SURPASS-CVOT, the first cardiovascular outcomes trial using an active incretin-based comparator, previously&amp;nbsp;demonstrated&amp;nbsp;that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events, including&amp;nbsp;CV&amp;nbsp;death, myocardial infarction, and stroke.&amp;nbsp;A&amp;nbsp;current analysis&amp;nbsp;expands&amp;nbsp;these findings by examining a wider spectrum of adverse events to further characterize the comparative cardiorenal effects of tirzepatide.&amp;nbsp; &amp;nbsp; In this interview, Matthew Martinez, MD, FACC&amp;nbsp;and Steven&amp;nbsp;E.&amp;nbsp;Nissen, MD, MACC&amp;nbsp;examine the&amp;nbsp;SURPASS-CVOT Randomized Clinical Trial.&amp;nbsp; ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://accelaccorg.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41991520/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/203867805